• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Medpace Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    3/31/25 4:14:19 PM ET
    $MEDP
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $MEDP alert in real time by email
    medp-20250328
    FALSE000166839700016683972025-03-282025-03-28

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    ______________________________________________________
    FORM 8-K
    ______________________________________________________
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (Date of earliest event reported): March 28, 2025
    ______________________________________________________
    Medpace Holdings, Inc.
    (Exact name of Registrant as Specified in Its Charter)
    ______________________________________________________
    Delaware001-3785632-0434904
    (State or Other Jurisdiction
    of Incorporation)
    (Commission File Number)(IRS Employer
    Identification No.)
    5375 Medpace Way
    Cincinnati, Ohio
    45227
    (Address of Principal Executive Offices)(Zip Code)
    Registrant’s Telephone Number, Including Area Code: 513 579-9911
    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)
    ______________________________________________________
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    o
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    o
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
    Securities registered pursuant to Section 12(b) of the Act:
    Title of each classTrading
    Symbol(s)
    Name of each exchange on which registered
    Common Stock $0.01 par valueMEDPNASDAQ Global Select Market
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
    Emerging growth company o
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o



    Item 1.01 Entry into a Material Definitive Agreement.
    On March 28, 2025, Medpace Holdings, Inc., a Delaware corporation (the "Company"), through its wholly owned subsidiaries, Medpace, Inc., as borrower, and Medpace IntermediateCo, Inc., as guarantor, entered into Amendment No.7 to Loan Documents (“Amendment No. 7”) with PNC Bank, National Association in connection with the Company’s unsecured credit facility (the “Loan Documents”). Amendment No. 7 extends the expiration date of the revolving credit note to March 31, 2026.

    The foregoing description of Amendment No. 7 is qualified in its entirety by reference to Amendment No. 7. A copy of Amendment No. 7 is filed herewith as Exhibit 10.1 and incorporated herein by reference.

    Item 9.01 Financial Statements and Exhibits.
    (d) Exhibits
    Exhibit No.Description
    10.1
    Amendment No. 7 dated March 28, 2025 to Loan Documents
    104Cover Page Interactive Data File (embedded within the Inline XBRL document)



    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
    MEDPACE HOLDINGS, INC.
    Date:March 31, 2025By:/s/ Kevin M. Brady
    Kevin M. Brady
    Chief Financial Officer

    Get the next $MEDP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MEDP

    DatePrice TargetRatingAnalyst
    6/24/2025$300.00Equal Weight
    Barclays
    4/22/2025Outperform → Mkt Perform
    William Blair
    4/14/2025$328.00Buy → Hold
    TD Cowen
    3/24/2025$330.00Market Perform
    Leerink Partners
    10/23/2024$413.00 → $349.00Outperform → Neutral
    Robert W. Baird
    10/14/2024Buy
    Redburn Atlantic
    9/27/2024$420.00 → $350.00Buy → Neutral
    UBS
    9/25/2024$415.00 → $345.00Buy → Hold
    Jefferies
    More analyst ratings